Get started
Author

Philip R. Mallinder

Observed names: P.R. Mallinder, Philip Mallinder, Philip R Mallinder
Observed institution: AstraZeneca (United Kingdom)
OpenAlex ID: A5113860440
Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase
2008 · Elsa D Garcin, Andrew S Arvai, et al. · Nature Chemical Biology · 276
Late Intervention with a Myeloperoxidase Inhibitor Stops Progression of Experimental Chronic Obstructive Pulmonary Disease
2011 · Andrew Churg, Caroline V. Marshall, et al. · American Journal of Respiratory and Critical Care Medicine · 114
Identification of a Putative Intracellular Allosteric Antagonist Binding-Site in the CXC Chemokine Receptors 1 and 2
2008 · David J. Nicholls, Nick P. Tomkinson, et al. · Molecular Pharmacology · 83
Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
2020 · Ani S. Balmanoukian, Jeffrey R. Infante, et al. · Clinical Cancer Research · 57
PDF
A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
2017 · Rebecca Leyland, Amanda Watkins, et al. · Clinical Cancer Research · 52
Whole-Molecule Antibody Engineering: Generation of a High-Affinity Anti-IL-6 Antibody with Extended Pharmacokinetics
2011 · Donna K. Finch, Matthew A. Sleeman, et al. · Journal of Molecular Biology · 44
Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1
2019 · Katherine A. Vousden, Tomas Lundqvist, et al. · Scientific Reports · 32
PDF
Detection of an activating c-kit mutation by real-time PCR in patients with anaphylaxis
2005 · Wendy Lawley, Heather Hird, et al. · Mutation research. Fundamental and molecular mechanisms of mutagenesis · 29
Engineering a High-Affinity Anti-IL-15 Antibody: Crystal Structure Reveals an α-Helix in VH CDR3 as Key Component of Paratope
2010 · David C. Lowe, Stefan Gerhardt, et al. · Journal of Molecular Biology · 25
E. coli expression and purification of human and cynomolgus IL-15
2009 · Alison Ward, Malcolm Anderson, et al. · Protein Expression and Purification · 21
Purification and characterization of recombinant rat mast cell protease 7 expressed in Pichia pastoris
2002 · Carolyn Lawson, Craig Walker, et al. · Protein Expression and Purification · 5
Identification of iNOS Inhibitors Using InteraX™
2009 · Philip R. Mallinder, Alan V. Wallace, et al. · SLAS DISCOVERY · 3
Supplementary figures from A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
2023 · Rebecca Leyland, Amanda Watkins, et al.
Supporting information tracked changes from A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
2023 · Rebecca Leyland, Amanda Watkins, et al.
Supporting information from A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
2023 · Rebecca Leyland, Amanda Watkins, et al.
Supplementary Figure 2 from Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
2023 · Ani S. Balmanoukian, Jeffrey R. Infante, et al.
Supplementary Table 1 from Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
2023 · Ani S. Balmanoukian, Jeffrey R. Infante, et al.
Supplementary Figure 4 from Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
2023 · Ani S. Balmanoukian, Jeffrey R. Infante, et al.
PDF
Supplementary Figure 1 from Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
2023 · Ani S. Balmanoukian, Jeffrey R. Infante, et al.
PDF
Supplementary Figure 3 from Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
2023 · Ani S. Balmanoukian, Jeffrey R. Infante, et al.
PDF
Supporting information from A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
2023 · Rebecca Leyland, Amanda Watkins, et al.
Supporting information tracked changes from A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
2023 · Rebecca Leyland, Amanda Watkins, et al.
Supplementary Figure 2 from Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
2023 · Ani S. Balmanoukian, Jeffrey R. Infante, et al.
PDF
Supplementary Figure 3 from Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
2023 · Ani S. Balmanoukian, Jeffrey R. Infante, et al.
Data from A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
2023 · Rebecca Leyland, Amanda Watkins, et al.
Works count: 34
Citation count: 741
H-index: 10
I10-index: 10
Year
Topic
Type